HomePTKFY • OTCMKTS
PT Kalbe Farma Unsponsored Indonesia ADR
$17.06
Feb 5, 12:20:08 AM GMT-5 · USD · OTCMKTS · Disclaimer
US listed security
Previous close
$17.05
Day range
$17.06 - $17.06
Year range
$16.38 - $23.73
Market cap
59.77T IDR
Avg Volume
305.00
Market news
Financials
Income Statement
Revenue
Net income
(IDR)Sep 2024Y/Y change
Revenue
7.91T7.16%
Operating expense
2.29T15.55%
Net income
573.28B6.97%
Net profit margin
7.25-0.14%
Earnings per share
12.417.73%
EBITDA
874.81B1.14%
Effective tax rate
23.01%—
Total assets
Total liabilities
(IDR)Sep 2024Y/Y change
Cash and short-term investments
4.32T45.45%
Total assets
28.75T5.78%
Total liabilities
4.84T0.67%
Total equity
23.91T—
Shares outstanding
46.15B—
Price to book
0.04—
Return on assets
6.15%—
Return on capital
7.16%—
Net change in cash
(IDR)Sep 2024Y/Y change
Net income
573.28B6.97%
Cash from operations
1.16T22.56%
Cash from investing
-176.64B33.78%
Cash from financing
-421.11B51.91%
Net change in cash
481.86B1,978.42%
Free cash flow
752.00B13.84%
About
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
Founded
Sep 10, 1966
Employees
12,924
Search
Clear search
Close search
Google apps
Main menu